Reed Jobs, the son of Apple co-founder Steve Jobs, is more interested in discussing his oncology-focused venture firm than his family legacy. During a recent video call, he quickly deflected a question about his laptop choice with a joking retort, eager to steer the conversation toward Yosemite, the firm he launched in 2023. Main Developments Yosemite operates at the intersection of philanthropy and investment, using outside capital to build biotech companies from early academic research. Jobs describes himself as motormouthed and self-deprecating, often employing video-game analogies, but his ambition is serious: he sees artificial intelligence accelerating both drug discovery and clinical trial design. Background Jobs launched Yosemite in 2023 with a mission to commercialize early-stage oncology research. Three years in, the firm aims to become a significant player in biotech, driven by the expanding opportunities that AI presents for faster drug development and more efficient clinical trials. Read also: Ninja Slushi Twist: Dual-Chamber Machine Beat NYC Heat Wave Why It Matters The intersection of AI and oncology could reshape how new treatments reach patients. Jobs' approach—combining philanthropic goals with venture capital—may offer a model for funding high-risk, high-reward medical research that traditional investors often avoid. What's Next Yosemite is expected to continue identifying promising academic research and scaling it into viable companies. Jobs has indicated that AI's impact on the field is growing faster than anticipated, suggesting more aggressive investment in the coming years.